Posted by Michael Wonder on 23 Jul 2018
Rhythm Pharmaceuticals receives European Medicines Agency PRIME designation for setmelanotide in rare genetic disorders of obesity
23 July 2018 - Program offers enhanced support for development of medicines that target unmet medical needs.
Rhythm Pharmaceuticals today announced that the EMA has granted PRIority MEdicines (PRIME) designation for setmelanotide, the Company’s first-in-class melanocortin-4 receptor (MC4R) agonist, for the treatment of obesity and the control of hunger associated with deficiency disorders of the MC4R pathway.
Rhythm has completed pivotal enrollment in two ongoing Phase 3 clinical trials evaluating setmelanotide in pro-opiomelanocortin and leptin receptor deficiency obesity and expects to report initial data in the third quarter of 2019.
